Clostridioides difficile (bacteria)

Immuron Receives European Patent on Drug Composition to Treat Clostridioides difficile Associated Disease

Retrieved on: 
Tuesday, January 17, 2023

Notification of the decision to grant European Patent 14784945.9, entitled “Methods and Compositions for the treatment and/or prophylaxis of Clostridium difficile associated disease,” was formally received yesterday, and grant of this application will be published in the European Patent Bulletin on 25 January 2023 under European Patent No.

Key Points: 
  • Notification of the decision to grant European Patent 14784945.9, entitled “Methods and Compositions for the treatment and/or prophylaxis of Clostridium difficile associated disease,” was formally received yesterday, and grant of this application will be published in the European Patent Bulletin on 25 January 2023 under European Patent No.
  • The company previously reported it had received notification from the European Patent Office of the intent to grant in July last year (ASX announcement July 7, 2022).
  • The European registration adds to Immuron's patent position for compositions and methods for the treatment and/or prophylaxis of Clostridioides difficile associated disease in Australia, New Zealand and the United States.
  • Clostridioides difficile (previously known as Clostridium difficile) infection (CDI) is a disease of the large intestine caused by toxins produced by the spore forming bacterium Clostridioides difficile.

SAB Biotherapeutics’ CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech Showcase

Retrieved on: 
Monday, January 9, 2023

Dr. Kropotova’s presentation, titled: Next Generation Biologics in Immunology: Solution for Complex Diseases, will discuss the latest innovations and treatment pathways in immunology, including an overview of SAB’s novel DiversitAb™ platform.

Key Points: 
  • Dr. Kropotova’s presentation, titled: Next Generation Biologics in Immunology: Solution for Complex Diseases, will discuss the latest innovations and treatment pathways in immunology, including an overview of SAB’s novel DiversitAb™ platform.
  • DiversitAb™ is the only platform in the world that produces fully-human, broadly neutralizing, polyclonal antibodies utilizing transchromosomic cows.
  • Dr. Kropotova will also present data from completed clinical trials that indicate SAB’s polyclonal antibody therapies can provide long-lasting efficacy against numerous highly mutating pathogens or multiple targets or pathways at once.
  • “SAB’s approach is to develop treatments designed to address multiple dysregulated pathways, multiple disease targets, and multiple epitopes in one powerful treatment,” said Dr. Kropotova.

SAB Biotherapeutics CMO Selected to Present at the January 2023 Biotech Showcase in San Francisco

Retrieved on: 
Thursday, December 15, 2022

The conference is taking place Jan. 9-11 in San Francisco, in parallel with the J.P. Morgan 41st Annual Health Care Conference.

Key Points: 
  • The conference is taking place Jan. 9-11 in San Francisco, in parallel with the J.P. Morgan 41st Annual Health Care Conference.
  • Alexandra Kropotova, MD, Executive Vice President, and Chief Medical Officer of SAB Biotherapeutics, will present at the Showcase on Tuesday, January 10 at 2:30pm PT.
  • SAB currently has multiple drug development programs underway and collaborations with the US government and global pharmaceutical companies.
  • For more information on SAB, visit: https://www.SAb.bio/ and follow SAB on Twitter and LinkedIn .

SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock

Retrieved on: 
Wednesday, December 7, 2022

Existing SAB investors – including T. Denny Sanford, an experienced biotech investor and healthcare philanthropist -- as well as new institutional investors participated in the private placement.

Key Points: 
  • Existing SAB investors – including T. Denny Sanford, an experienced biotech investor and healthcare philanthropist -- as well as new institutional investors participated in the private placement.
  • The aggregate gross proceeds from the offering are approximately $7.9 million, based on the offering price of $1.08 which was the 5-day average closing price ending December 5, 2022, for each share of the Company's common stock plus one Warrant.
  • The Company expects to use net proceeds from the private placement to advance the Company’s pipeline of its first-in-class product candidates for Clostridioides difficile (C.
  • For more information on SAB, visit: https://www.SAb.bio/ and follow SAB on Twitter and LinkedIn .

SAB Biotherapeutics Provides Company Update for Q3 2022 Financial Results

Retrieved on: 
Tuesday, November 15, 2022

SIOUX FALLS, S.D., Nov. 15, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today reported financial results for the third quarter ended September 30, 2022, and provided a company update.

Key Points: 
  • SIOUX FALLS, S.D., Nov. 15, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today reported financial results for the third quarter ended September 30, 2022, and provided a company update.
  • The SAB fully-human polyclonal antibody platform maintains its efficacy against multiple variants of several highly mutating viruses.
  • Financial Guidance: SAB received $8.6 million from the DoD contract on November 10, 2022, for work performed.
  • SAB Biotherapeutics, Inc. (SAB) We are a clinical-stage biopharmaceutical company focused on the development of powerful and proprietary immunotherapeutic polyclonal human antibodies to treat and prevent infectious diseases and immune and autoimmune disorders.

CHOP-led Study Shows that Antibiotic-Resistant Microbes in the Gut Make C. difficile More Infectious

Retrieved on: 
Wednesday, November 16, 2022

PHILADELPHIA, Nov. 16, 2022 /PRNewswire/ -- Clostridioides difficile, often referred to as C. difficile or C. diff, is a bacterium that causes severe intestinal illness and, as its name suggests, can be difficult to study and treat. Approximately 1 in 6 patients infected with C. difficile will be reinfected within two months. Yet scientists have not figured out why C. difficile infection is more difficult to treat in some patients versus others. The human gut is filled with trillions of microbes, and these microbes influence the virulence of various pathogens, but until now, scientists had little understanding of how C. difficile cooperates with the rich collection of microorganisms in the gastrointestinal tract.

Key Points: 
  • Yet scientists have not figured out why C. difficile infection is more difficult to treat in some patients versus others.
  • Prior studies have shown that adults infected with C. difficile also have high levels of Enterococcus in their gut and that vancomycin-resistant Enterococcus (VRE) frequently co-infects patients with C. difficile.
  • They also observed a positive correlation between C. difficile burdens and ornithine, supporting a key role for this amino acid in C. difficile infection.
  • difficile."

UMF Corporation Calls for Nominations for 14th Annual National Hygiene Specialist® Excellence Award

Retrieved on: 
Thursday, November 10, 2022

NORTHBROOK, Ill., Nov. 10, 2022 /PRNewswire/ -- UMF Corporation is pleased to announce that nominations are open for the 14th annual National Hygiene Specialist® Excellence Award, which acknowledges the environmental services (EVS) workers who play essential roles in reducing preventable healthcare associated infections (pHAIs). pHAIs are among the leading causes of death in the United States. Infecting 1 in 25 hospitalized patients annually, pHAIs put patients at risk, significantly increase the number of hospital days required, and add to healthcare costs. EVS staff are crucial when it comes to controlling pHAIs, which include superbugs such as Methicillin-resistant Staphylococcus aureus (MRSA), Clostridioides difficile (C. diff), Vancomycin-resistant Enterococcus (VRE), and COVID-19. Nominations are open through Dec. 31, 2022.

Key Points: 
  • NORTHBROOK, Ill., Nov. 10, 2022 /PRNewswire/ -- UMF Corporation is pleased to announce that nominationsare open for the 14th annual National Hygiene Specialist Excellence Award , which acknowledges the environmental services (EVS) workers who play essential roles in reducing preventable healthcare associated infections (pHAIs).
  • "In the United States, infections acquired in healthcare facilities kill more than 75,000 people every year," said UMF CEO George Clarke.
  • While we established our National Hygiene Specialist Excellence Award more than a decade ago, it has never been more important to acknowledge and celebrate these workers who serve as a first line of defense in preventing the spread of pHAIs."
  • The National Hygiene Specialist Excellence Award is an opportunity to recognize their critical contributions.

 Pivotal Phase 3 Efficacy and Safety Data for Ferring’s RBX2660 Published in Drugs

Retrieved on: 
Monday, November 7, 2022

RBX2660 is an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrent CDI (rCDI) after antibiotic treatment.

Key Points: 
  • RBX2660 is an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrent CDI (rCDI) after antibiotic treatment.
  • The published manuscript, titled, Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial With a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection is available online .
  • Participants were followed up to eight weeks for the primary efficacy analysis, and up to six months for efficacy and safety analyses.
  • Participants were followed up to eight weeks for the efficacy analysis, and up to 24 months for the safety analysis.

Acurx Pharmaceuticals, Inc. to Discuss 2022 Third Quarter Financial Results on November 14, 2022 Conference Call and Provide Business Update

Retrieved on: 
Tuesday, November 1, 2022

It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections.

Key Points: 
  • It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections.
  • The Company successfully completed Phase 1 and Phase 2a clinical trials of ibezapolstat.
  • The CDC has designated C. difficile as an urgent threat highlighting the need for new antibiotics to treat CDI.
  • Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections.

Ferring Presents Seven New Analyses at ACG 2022 for RBX2660, Its Investigational Microbiota-Based Live Biotherapeutic

Retrieved on: 
Monday, October 24, 2022

Ferring Pharmaceuticals today announced the presentation at the American College of Gastroenterology ( ACG ) 2022 Annual Scientific Meeting of seven analyses for RBX2660, an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrent C. difficile infection (CDI) after antibiotic treatment.

Key Points: 
  • Ferring Pharmaceuticals today announced the presentation at the American College of Gastroenterology ( ACG ) 2022 Annual Scientific Meeting of seven analyses for RBX2660, an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrent C. difficile infection (CDI) after antibiotic treatment.
  • Among responders, improvements from baseline to week 8 were statistically significant (all p
  • Adjusted analyses among responders found a difference favoring RBX2660 versus placebo at week 8 for the mental domain (7.4, 95% CI: [0.33, 14.43], P
  • Four additional analyses were presented at ACG 2022, which looked at the efficacy and safety of RBX2660 across different populations, including participants with underlying comorbidities.